
Customer Douglas J. Reece filed a class action lawsuit against JUUL and Altria on April 7 alleging that anticompetitive agreements between the two companies caused consumers to pay more for e-cigarettes. He claims the defendants restrained competition and violated federal antitrust laws. The suit comes days after the Federal Trade Commission (FTC) opened a similar investigation.
Altria allegedly purchased a 35% stake in JUUL shortly after announcing they were going to stop selling e-cigarettes in 2018. JUUL quickly rose to the top of the e-cigarette market with revenues growing 700% in 2017. Altria and JUUL entered their agreement in December of 2018 with Altria giving JUUL US$12.8 billion.
“Altria’s investment in JUUL and its exit from the market not only eliminated its existing e-cigarette product but also, through the Non-Compete, halted its ongoing innovation efforts toward developing a new and improved portfolio of products. Thus, consumers lost the benefit of current and future head-to-head competition between Altria and JUUL, and between Altria and other competitors,” the complaint states.
The plaintiff alleges JUUL and Altria’s actions deprived him and the rest of the class of the benefits of competition that antitrust laws are designed to protect. Reece is represented by Salim-Beasley. He is seeking damages for himself and the class, as well as injunctive relief through returning competition to the e-cigarette business. He claims the agreement was not beneficial, citing changes to the agreement in early 2020. “Defendants cannot show the transaction restricting competition resulted in cognizable efficiencies sufficient to outweigh the competitive harm caused by Altria’s agreement to exit the relevant market. Nor can Defendants point to pro-competitive benefits that could not have been achieved through less restrictive means,” Reece alleges.
The Federal Trade Commission filed an administrative complaint against JUUL Labs and Altria Group on April 1, 2020, investigating the same issue.
Full Content: Chicago Tribune
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas